UBS Ups Express Scripts Earnings Estimates, While Metabolix Target Reduced

The S&P 500 (NYSEARCA:SPY) is down 9 points today, or 0.73% and trades at 1,286. Here’s what brokerage analysts had to say today about the following companies:

Express Scripts Inc. (NASDAQ:ESRX): UBS raises Express Scripts.  Reacting to the Medco meger, UBS raised earnings estimates for 2012 and 2013 to well above consensus.  The merger is expected close mid-year.  The firm noted that 95 percent of prescription volume was retained from last year into this year. The firm reiterates its Buy and raises target from $53 to $66.

Metabolix, Inc. (NASDAQ:MBLX): Piper Jaffray lowers Metabolix target. After ADM (NYSE:ADM) terminated its joint venture with Metabolix, the firm says company strategy is unclear.  Cash balance provides management with a window to set a new course. The firm keeps a Neutral and lowers target from $5 to $3.

Equinix, Inc. (NASDAQ:EQIX): Cowen says Equinix may transition to a REIT. Cowen met with the company’s chief financial officer and feels Equinix will continue a balanced growth approach.  The firm noted a decreasing churn rate and management interest to transition to a real estate investment trust. Shares remain Outperform.

Oxford Industries Inc. (NYSE:OXM): Brean Murray raises Oxford Industries target. The company held and optimistic conference and Brean Murray cited expansion, inventory and margins as the firm raised target from $46 to $55. Shares are rated Buy.

Featured Reading: 9 Early Movers: Novartis Down Over 2%, JPM Reports Earnings, Metabolix Plummets 55%>>

To contact the reporter on this story: Jim Wilkerson at

To contact the editor responsible for this story: Damien Hoffman at